Companies in rapid pursuit of Btk immunokinase

  title={Companies in rapid pursuit of Btk immunokinase},
  author={Cormac Sheridan},
  journal={Nature Biotechnology},
  • C. Sheridan
  • Published 7 March 2012
  • Biology
  • Nature Biotechnology
On January 26, Celgene, of Summit, New Jersey, announced it would pay an initial $350 million for Avila Therapeutics. The acquisition highlights a growing interest in Bruton’s tyrosine kinase (Btk) inhibitors, a promising drug class already in development for B-cell malignancies and with additional potential in B cell–driven autoimmune disease. Celgene is betting that Avila’s Btk inhibitor AVL-292 and others will deliver the same kind of data that prompted a large development deal, disclosed on… 

Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

Cell biology: A key driver of therapeutic innovation

It is proposed that early, more strategic, support of cutting-edge academic research by industry may be more effective for translational purposes than the current model of a late selection of community-evolved projects.

Identification and Characterization of In Vitro Metabolites of Ibrutinib by Rat Liver Microsomes Using Ultra-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry

The detailed in vitro metabolite profiling of ibrutinib will be further helpful to predict the in vivo metabolism in the human body and will assist in predicting the effectiveness and toxicity of the drug.

Development and Validation of Novel and Highly Sensitive Stability-Indicating Reverse Phase Ultra Performance Liquid Chromatography Method for Quantification of Ibrutinib and its ten Degradation Products

In present study, a novel, simple, robust, stability-indicating, highly sensitive and specific reverse phase ultra-performance liquid chromatographic method was established and validated for the

The many faces of Bruton's tyrosine kinase

  • C. Mcatee
  • Medicine, Biology
    Nature Biotechnology
  • 2012